As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Subcommittee to Recommend Use of Most-recent 3-Year Averages in Drug Cost Calculation
October 27, 2011
-
REGULATORY DPJ Lawmakers Opposed to TPP Criticize MHLW at Hearings
October 27, 2011
-
BUSINESS GSK CEO Thinks Highly of Premiums for New Drug Creation, Key to Attractive Market
October 26, 2011
-
REGULATORY Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 26, 2011
-
BUSINESS “Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
October 25, 2011
-
BUSINESS Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
-
BUSINESS CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
-
REGULATORY Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 24, 2011
-
BUSINESS Abbott to Separate into 2 Companies
October 21, 2011
-
BUSINESS Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
-
REGULATORY MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
-
COMMENTARY Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
BUSINESS Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
-
ORGANIZATION Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
-
REGULATORY PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
-
BUSINESS MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
-
REGULATORY Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
-
REGULATORY MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
-
REGULATORY Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
-
BUSINESS Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
ページ
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…